炎症
免疫学
炎症性肠病
发病机制
白细胞介素23
医学
细胞因子
溃疡性结肠炎
T细胞
疾病
白细胞介素
封锁
受体
白细胞介素17
免疫系统
病理
内科学
作者
Takanori Kanai∥,Nobuhiko Kamada,Tadakazu Hisamatsu
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2013-10-31
卷期号:14 (12): 1392-1399
被引量:33
标识
DOI:10.2174/13894501113149990006
摘要
Interleukin 18 (IL-18) is an IL-1 super family cytokine that is involved in infection, inflammation and autoimmune diseases. Mounting evidence suggests that IL-18 exert a dual role in inflammation and homeostasis. IL-18 can act as a promoter of T cell immunities, such as type 1 and 17 helper T cell responses, and thus enhances T cell-mediated inflammation, whereas IL-18 increases the barrier function and regeneration of epithelial cells and protects the host from inflammatory stimuli. Although the functional role of IL-18 in regulation of inflammation remains controversial, accumulating evidence indicates the contribution of IL-18 to the pathogenesis of inflammatory bowel diseases (IBD). For example, levels of serum and/or mucosal IL-18 and IL-18 binding protein are elevated in the patients with IBD. Furthermore, polymorphisms in IL-18 and IL-18-related molecules, such as the IL-18 receptor and/or an IL-18 activator NLRP3, genes are found in the patients with IBD. Thus, these preclinical data imply that IL-18 can be a novel therapeutic target for the treatment of IBD. In this review, we focus on IL-18 biology and physiological roles in animal models and human IBD, to provide an outline for development of IL-18 blockade strategies. Keywords: IL-18, IL-18BP, inflammatory bowel disease, Crohn's disease, ulcerative colitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI